MET and neoplasm: In a large retrospective analysis of 1630 metastatic GEA patients using the tumor-agnostic Guardant360 hybrid-capture panel, Maron and colleagues identified key actionable alterations: HER2 amplified in 9.5%, FGFR2 in 7.7%, MET proto-oncogene, receptor tyrosine kinase (MET) in 5.6%, epidermal growth factor receptor (EGFR) in 4.9%, and MSI-H in 3.2% [29].